See more : Ascot Resources Ltd. (AOT.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Ceapro Inc. (CRPOF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ceapro Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- DV8 Public Company Limited (DV8.BK) Income Statement Analysis – Financial Results
- Joinn Laboratories(China)Co.,Ltd. (603127.SS) Income Statement Analysis – Financial Results
- Midland States Bancorp, Inc. (MSBIP) Income Statement Analysis – Financial Results
- Revenio Group Oyj (0KFH.L) Income Statement Analysis – Financial Results
- Sky Gold Corp. (SRKZF) Income Statement Analysis – Financial Results
Ceapro Inc. (CRPOF)
About Ceapro Inc.
Ceapro Inc., a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. It operates in two segments, Active Ingredient Product Technology Industry and Cosmeceutical Industry. The Active Ingredient Product Technology Industry segment develops proprietary extraction technologies and the application of these technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. The Cosmeceutical Industry segment is involved in the development and commercialization of anti-aging products derived from natural active ingredients sold directly to the end-user primarily through online website sales and through select natural products stores. The company was incorporated in 1997 and is headquartered in Edmonton, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.63M | 18.84M | 17.20M | 15.12M | 12.88M | 11.59M | 12.93M | 13.67M | 10.67M | 8.89M | 6.52M | 5.17M | 5.79M | 5.58M | 4.37M | 4.23M | 3.45M | 3.31M | 2.68M | 1.96M | 2.22M | 1.51M | 1.15M | 808.85K | 300.00K | 400.00K | 2.30M | 600.00K |
| Cost of Revenue | 6.07M | 7.82M | 7.51M | 7.50M | 7.43M | 5.45M | 5.65M | 4.32M | 3.64M | 4.13M | 3.43M | 2.72M | 2.54M | 3.04M | 2.25M | 2.64M | 1.79M | 1.73M | 1.12M | 1.02M | 928.12K | 754.13K | 728.41K | 517.68K | 200.00K | 100.00K | 1.90M | 500.00K |
| Gross Profit | 3.56M | 11.02M | 9.69M | 7.62M | 5.45M | 6.14M | 7.27M | 9.35M | 7.03M | 4.76M | 3.10M | 2.45M | 3.25M | 2.54M | 2.12M | 1.59M | 1.65M | 1.58M | 1.56M | 934.13K | 1.29M | 757.38K | 421.03K | 291.17K | 100.00K | 300.00K | 400.00K | 100.00K |
| Gross Profit Ratio | 36.99% | 58.48% | 56.35% | 50.41% | 42.28% | 52.95% | 56.26% | 68.40% | 65.89% | 53.58% | 47.50% | 47.41% | 56.13% | 45.46% | 48.47% | 37.53% | 47.97% | 47.70% | 58.13% | 47.73% | 58.16% | 50.11% | 36.63% | 36.00% | 33.33% | 75.00% | 17.39% | 16.67% |
| Research & Development | 2.75M | 1.79M | 3.78M | 1.88M | 2.39M | 2.67M | 1.61M | 919.12K | 625.21K | 578.36K | 731.17K | 856.19K | 996.72K | 774.06K | 0.00 | 0.00 | 695.66K | 365.42K | 162.83K | 302.49K | 353.74K | 259.06K | 397.00K | 293.43K | 400.00K | 800.00K | 2.30M | 100.00K |
| General & Administrative | 7.42M | 3.70M | 3.24M | 3.28M | 2.95M | 3.00M | 2.84M | 2.19M | 2.52M | 1.98M | 1.71M | 1.80M | 1.37M | 1.30M | 1.68M | 1.69M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 40.48K | 29.56K | 47.12K | 111.04K | 425.23K | 225.55K | 32.11K | 4.33K | 7.62K | 13.70K | 84.90K | 198.65K | 111.36K | 69.51K | 183.69K | 385.13K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.07M | 3.73M | 3.29M | 3.39M | 3.38M | 3.23M | 2.87M | 2.19M | 2.53M | 2.00M | 1.79M | 1.99M | 1.49M | 1.37M | 1.86M | 2.07M | 1.68M | 1.36M | 1.24M | 963.92K | 1.27M | 814.11K | 691.92K | 777.79K | 800.00K | 1.10M | 3.70M | 1.80M |
| Other Expenses | 129.31K | 181.46K | 273.12K | -93.71K | -353.32K | -1.12M | -738.09K | -629.30K | 0.00 | 0.00 | 0.00 | 0.00 | -7.34K | -479.44K | -219.38K | -2.29M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 9.82M | 5.52M | 7.07M | 5.28M | 5.77M | 5.17M | 6.63M | 3.11M | 3.15M | 2.58M | 2.53M | 2.85M | 2.48M | 1.43M | 1.90M | 2.81M | 2.17M | 1.87M | 1.56M | 1.36M | 1.68M | 1.10M | 1.11M | 1.10M | 1.20M | 2.00M | 8.20M | 2.20M |
| Cost & Expenses | 15.89M | 13.34M | 14.57M | 12.77M | 13.21M | 10.62M | 12.29M | 7.43M | 6.79M | 6.70M | 5.95M | 5.57M | 5.02M | 4.47M | 4.16M | 5.45M | 3.96M | 3.61M | 2.69M | 2.38M | 2.61M | 1.85M | 1.84M | 1.62M | 1.40M | 2.10M | 10.10M | 2.70M |
| Interest Income | 436.22K | 93.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.55K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 100.00K |
| Interest Expense | 128.13K | 129.97K | 151.89K | 175.16K | 201.50K | 48.05K | 20.03K | 37.59K | 52.78K | 63.51K | 126.66K | 112.90K | 180.81K | 110.90K | 77.03K | 83.65K | 43.83K | 46.35K | 51.70K | 28.50K | 47.77K | 93.56K | 113.22K | 94.93K | 0.00 | 100.00K | 0.00 | 100.00K |
| Depreciation & Amortization | 1.95M | 1.91M | 1.88M | 1.84M | 1.83M | 578.60K | 326.10K | 359.45K | 392.32K | 296.38K | 292.64K | 292.53K | 297.28K | 290.64K | 356.96K | 336.57K | 120.44K | 146.78K | 161.55K | 91.96K | 59.96K | 23.57K | 24.25K | 27.99K | 0.00 | 100.00K | 2.20M | 300.00K |
| EBITDA | -4.31M | 7.54M | 4.72M | 4.04M | 1.10M | 371.48K | 110.92K | 6.40M | 4.08M | 2.36M | 866.33K | -109.12K | 1.06M | 1.41M | 571.46K | -889.10K | -393.57K | -148.94K | 158.33K | -332.28K | -330.37K | -315.78K | -667.88K | -780.05K | -1.10M | -1.60M | -5.60M | -1.80M |
| EBITDA Ratio | -44.73% | 40.00% | 27.46% | 26.71% | 8.52% | 3.20% | 0.86% | 46.78% | 38.20% | 26.54% | 13.28% | -2.11% | 18.37% | 25.22% | 13.08% | -21.03% | -11.42% | -4.50% | 5.90% | -16.98% | -14.89% | -20.89% | -58.10% | -96.44% | -366.67% | -400.00% | -243.48% | -300.00% |
| Operating Income | -6.26M | 5.31M | 2.42M | 2.12M | -586.66K | 128.08K | 2.66M | 6.00M | 3.63M | 2.00M | 447.03K | -514.55K | 584.91K | 992.80K | 137.47K | -1.31M | -514.01K | 21.64K | -3.22K | -424.24K | -390.33K | -339.35K | -692.14K | -808.04K | -1.10M | -1.70M | -7.80M | -2.10M |
| Operating Income Ratio | -64.93% | 28.21% | 14.05% | 13.99% | -4.55% | 1.10% | 20.55% | 43.87% | 34.03% | 22.49% | 6.85% | -9.96% | 10.11% | 17.80% | 3.15% | -30.97% | -14.91% | 0.65% | -0.12% | -21.68% | -17.60% | -22.45% | -60.21% | -99.90% | -366.67% | -425.00% | -339.13% | -350.00% |
| Total Other Income/Expenses | 350.72K | 277.94K | -4.61K | -490.51K | -810.06K | -1.05M | -1.07M | -878.91K | -658.56K | -596.51K | -401.99K | -23.81K | -7.34K | 310.10K | -219.38K | -2.29M | -875.32K | -294.00K | -53.79K | 26.51K | 553.01K | 462.33K | 459.25K | -12.92K | 100.00K | -12.50M | -11.00M | -1.40M |
| Income Before Tax | -5.90M | 5.78M | 2.62M | 1.86M | -1.14M | -921.23K | -426.82K | 5.36M | 3.83M | 1.59M | 175.81K | -538.35K | 577.57K | 501.08K | -81.90K | -3.60M | -1.39M | -272.36K | -57.01K | -397.74K | 442.04K | 115.77K | -232.88K | -820.96K | -1.00M | -14.20M | -18.80M | -3.50M |
| Income Before Tax Ratio | -61.29% | 30.66% | 15.23% | 12.27% | -8.82% | -7.95% | -3.30% | 39.22% | 35.94% | 17.93% | 2.69% | -10.42% | 9.98% | 8.99% | -1.87% | -85.13% | -40.30% | -8.23% | -2.12% | -20.32% | 19.93% | 7.66% | -20.26% | -101.50% | -333.33% | -3,550.00% | -817.39% | -583.33% |
| Income Tax Expense | -1.19M | 1.38M | -223.69K | 81.45K | -3.41K | -605.69K | 531.46K | 1.74M | -1.09M | 63.51K | 126.66K | 112.90K | 180.81K | 123.18K | 64.48K | 83.65K | 369.93K | 46.35K | 51.70K | 28.50K | 47.77K | 93.56K | 113.22K | 94.93K | -100.00K | 100.00K | 1.00M | 200.00K |
| Net Income | -4.71M | 4.40M | 3.37M | 1.86M | -1.13M | -315.54K | -958.28K | 3.62M | 4.92M | 1.59M | 175.81K | -538.35K | 577.57K | 463.72K | -69.35K | -3.60M | -1.39M | -272.36K | -57.01K | -397.74K | 442.04K | 115.77K | -346.10K | -915.90K | -900.00K | -14.30M | -19.80M | -3.70M |
| Net Income Ratio | -48.89% | 23.34% | 19.57% | 12.27% | -8.79% | -2.72% | -7.41% | 26.47% | 46.14% | 17.93% | 2.69% | -10.42% | 9.98% | 8.32% | -1.59% | -85.13% | -40.30% | -8.23% | -2.12% | -20.32% | 19.93% | 7.66% | -30.11% | -113.23% | -300.00% | -3,575.00% | -860.87% | -616.67% |
| EPS | -0.06 | 0.06 | 0.04 | 0.02 | -0.01 | 0.00 | -0.01 | 0.05 | 0.08 | 0.03 | 0.00 | -0.01 | 0.01 | 0.01 | 0.00 | -0.08 | -0.03 | -0.01 | 0.00 | -0.01 | 0.01 | 0.00 | -0.01 | -0.04 | -0.04 | -0.79 | -1.27 | -0.20 |
| EPS Diluted | -0.06 | 0.06 | 0.04 | 0.02 | -0.01 | 0.00 | -0.01 | 0.05 | 0.08 | 0.03 | 0.00 | -0.01 | 0.01 | 0.01 | 0.00 | -0.08 | -0.03 | -0.01 | 0.00 | -0.01 | 0.01 | 0.00 | -0.01 | -0.04 | -0.04 | -0.79 | -1.27 | -0.20 |
| Weighted Avg Shares Out | 78.27M | 77.96M | 77.67M | 77.59M | 77.19M | 76.20M | 75.34M | 67.68M | 61.80M | 60.90M | 60.28M | 60.28M | 56.56M | 53.22M | 49.58M | 47.05M | 42.34M | 37.19M | 36.34M | 39.77M | 31.57M | 28.94M | 29.36M | 21.23M | 22.50M | 18.10M | 15.59M | 18.50M |
| Weighted Avg Shares Out (Dil) | 78.27M | 78.58M | 78.59M | 78.14M | 77.19M | 76.20M | 75.34M | 71.33M | 65.20M | 62.53M | 60.28M | 60.28M | 56.56M | 53.22M | 49.58M | 47.05M | 42.34M | 37.19M | 36.34M | 39.77M | 34.00M | 28.94M | 29.36M | 21.23M | 22.50M | 18.10M | 15.59M | 18.50M |
Ceapro Inc. to Present at the H.C. Wainwright Global Life Sciences Conference
EDMONTON, Alberta, March 03, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles...
Ceapro Inc. to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference
EDMONTON, Alberta, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles...
Ceapro Inc. Reports 2020 Third Quarter and Nine-Month Financial Results and Operational Highlights
– R&D activities focused on advancing the development of innovative delivery systems and yeast beta glucan as a potential inhalable therapeutic for COVID-19 –
Source: https://incomestatements.info
Category: Stock Reports